Teva Stock Surges After FDA Approves New Monthly Schizophrenia Injection
Translated & summarized from Globes by baba
Teva's stock surged nearly 4.5% in early Wall Street trading after receiving FDA approval for WELTRUZA, a new monthly injectable treatment for schizophrenia. The drug has shown significant improvements in clinical trials for adult patients. Teva will host an investor call today, and the company's market valuation reached $47.8 billion.
The story in 5 lines · by baba
- Teva's stock rose approximately 4.5% after the FDA approved its new schizophrenia drug, WELTRUZA.
- WELTRUZA is the first monthly injectable treatment for adults with schizophrenia.
- Clinical trials showed WELTRUZA improved symptoms, reduced severity, and enhanced functioning.
- Dr. Eric Hughes highlighted the drug's innovation and removal of post-injection monitoring.
- The approval led to Teva's market valuation reaching $47.8 billion in early trading.
Teva Pharmaceutical Industries Ltd. saw its stock price jump approximately 4.5% in early trading on Wall Street following the U.S. Food and Drug Administration's (FDA) approval of its new schizophrenia treatment. The drug, named WELTRUZA, is the first monthly injectable therapy for adults diagnosed with schizophrenia. Teva announced that it will hold an investor call later today at 3:00 PM.
According to Teva, WELTRUZA is a novel, long-acting subcutaneous injection designed for adult schizophrenia patients. Clinical trials demonstrated significant improvements in disease symptoms, reduced severity, and enhanced personal and social functioning. Dr. Eric Hughes, Teva's Senior Vice President, Head of Global R&D, and Chief Medical Officer, stated that WELTRUZA combines proven science with innovative formulation, eliminating the need for post-injection monitoring and addressing a major barrier in treatment.
The company's stock reached a market valuation of $47.8 billion during early trading. The article also briefly mentions a separate piece about smart medical records.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Centre 1Right 2Other 5
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.